Inhaled mist could boost lung cancer treatment before surgery
NCT ID NCT06694454
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times
Summary
This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. About 60 adults with operable stage IB-IIIA NSCLC will receive the inhaled drug plus durvalumab and platinum-based chemo for three cycles, then undergo tumor removal. The goal is to find the safest and most effective dose and see if it can wipe out all cancer cells in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacytidine (inhaled), carboplatin, paclitaxel, durvalumab
What this could lead to
If this works, it could improve the chance of eliminating all cancer before surgery for early-stage lung cancer patients, potentially reducing recurrence.
What could go wrong
This is an early phase 1/2 trial with only 60 participants, so results may not apply to everyone. The inhaled drug is experimental for lung cancer, and side effects from the combination therapy could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.